A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy

Prior treatment

• Previous splenectomy.

Other illness

• Presence or suspicion of a systemic active bacterial, viral, or fungal infection
• History of infection with capsular bacteria (e.g., meningococcus, pneumococcus, etc.)
• Positive of HIV, HBsAg or HCVAb.
• History of recurrent invasive infections caused by encapsulated organisms,e.g. meningococcus or pneumococcus.
• A history of malignancy within 5 years before screening

Lab values

• Patients with reticulocytes \<100x10\^9/L; platelets \<30x10\^9/L; neutrophils \<0.5x10\^9/L.

Other

• Known or suspected hereditary or acquired complement deficiency;

• Male and female participants ≥ 18 years of age and BMI ≥ 18.0 kg/m2 with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with clone size≥10%.
• Mean hemoglobin level \<100 g/L at screening.
• LDH \> 1.5 x Upper Limit of Normal (ULN) at screening.
• Vaccination against Neisseria meningitidis infection is required prior to the
• start of study treatment. If not received previously, vaccination against
• Streptococcus pneumoniae and Haemophilus influenzae infections should be given.